Expertise in
5
conditions

Dr. Jan Westerman

Intensive Care Medicine
Baptist Health Center Pulmonary
Jasper, AL 
Offers Telehealth
Expertise in
5
conditions
Baptist Health Center Pulmonary
Jasper, AL 

Overview

Jan Westerman is an Intensive Care Medicine provider practicing medicine in Jasper, Alabama.

Dr. Westerman is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease (COPD), Excessive Daytime Sleepiness, Gastrostomy, and Endoscopy.

He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 9 clinical trials.

Specialties

Intensive Care Medicine

Licenses

Critical Care Medicine in NC

Hospital Affiliations

Walker Baptist Medical Center
Fayette Medical Center
North Alabama Medical Center
Northwest Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VIVA Health
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Baptist Health Center Pulmonary
Jasper, AL 35501
Other Locations
Summit Sleep Disorders Center LLC
Jasper, AL 35501

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
Enrollment Status: Active_not_recruiting
Publish Date: May 14, 2026
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-1)
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-1)
Enrollment Status: Completed
Publish Date: May 05, 2026
Intervention Type: Device, Drug
Study Drug: Treprostinil
Study Phase: Phase 3
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
Enrollment Status: Completed
Publish Date: August 15, 2025
Intervention Type: Drug, Biological
Study Drug: Mepolizumab
Study Phase: Phase 3
A Phase I/II, Observer-blind, Randomised, Placebo-controlled Study to Assess Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)
A Phase I/II, Observer-blind, Randomised, Placebo-controlled Study to Assess Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)
Enrollment Status: Completed
Publish Date: May 08, 2025
Intervention Type: Biological
Study Phase: Phase 2
A 2-Part, 2-Arm, Phase 2, Randomized, Double-Blind, Placebo-Controlled Study on the Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection
A 2-Part, 2-Arm, Phase 2, Randomized, Double-Blind, Placebo-Controlled Study on the Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection
Enrollment Status: Terminated
Publish Date: October 08, 2024
Intervention Type: Drug
Study Drug: Niclosamide
Study Phase: Phase 2
A Phase 2 Randomized, Double-blind, Placebo-controlled Trial and Open Label Extension to Evaluate the Safety and Efficacy of Deupirfenidone (LYT-100) in Post-acute COVID-19 Respiratory Disease
A Phase 2 Randomized, Double-blind, Placebo-controlled Trial and Open Label Extension to Evaluate the Safety and Efficacy of Deupirfenidone (LYT-100) in Post-acute COVID-19 Respiratory Disease
Enrollment Status: Terminated
Publish Date: February 14, 2024
Intervention Type: Drug, Other
Study Drug: Deupirfenidone
Study Phase: Phase 2
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: October 16, 2023
Intervention Type: Drug
Study Drug: Ensifentrine
Study Phase: Phase 3
Fitbit Sleep Apnea Alert Software Validation Study
Fitbit Sleep Apnea Alert Software Validation Study
Enrollment Status: Unknown
Publish Date: August 22, 2022
Intervention Type: Diagnostic test
A Comparison of the Clinical Effectiveness of Inhaled Triple Therapy (Fluticasone Furoate / Umeclidinium Bromide / Vilanterol) in a Single Inhaler (TRELEGY™ ELLIPTA™) With Inhaled Non-ELLIPTA™ Multiple Inhaler Triple Therapies in COPD Patients in the US Within a Usual Care Setting in a Prospective Pre-Post Study
A Comparison of the Clinical Effectiveness of Inhaled Triple Therapy (Fluticasone Furoate / Umeclidinium Bromide / Vilanterol) in a Single Inhaler (TRELEGY™ ELLIPTA™) With Inhaled Non-ELLIPTA™ Multiple Inhaler Triple Therapies in COPD Patients in the US Within a Usual Care Setting in a Prospective Pre-Post Study
Enrollment Status: Withdrawn
Publish Date: April 22, 2020
Intervention Type: Drug
Study Phase: Phase 4
View 8 Less Clinical Trials

1 Total Publications

The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease.
The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease.
Journal: Pulmonary pharmacology & therapeutics
Published: March 17, 2015
Similar Doctors
Expertise in
21
conditions
Dr. Tracy Luckhardt
Intensive Care Medicine
Expertise in
21
conditions
Dr. Tracy Luckhardt
Intensive Care Medicine
Referral may be required

University Of Alabama Health Services Foundation PC

2000 6th Ave S, 
Birmingham, AL 
 (359.6 miles away)
205-996-5864
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tracy Luckhardt is an Intensive Care Medicine provider practicing medicine in Birmingham, Alabama. Dr. Luckhardt is highly rated in 21 conditions, according to our data. Her clinical expertise encompasses Acute Interstitial Pneumonia, Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, and Pulmonary Fibrosis.

Expertise in
9
conditions
Dr. Tejaswini Kulkarni
Intensive Care Medicine
Expertise in
9
conditions
Dr. Tejaswini Kulkarni
Intensive Care Medicine
Referral may be required

UAB Hospital Birmingham

619 19th St S, 
Birmingham, AL 
 (359.7 miles away)
205-934-4011
Experience:
17+ years
Languages Spoken:
English
See accepted insurances

Tejaswini Kulkarni is an Intensive Care Medicine provider practicing medicine in Birmingham, Alabama. She has been practicing medicine for over 17 years. Dr. Kulkarni is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Acute Interstitial Pneumonia, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Lung Transplant, and Endoscopy.

Expertise in
14
conditions
Dr. Mark Dransfield
Intensive Care Medicine
Expertise in
14
conditions
Dr. Mark Dransfield
Intensive Care Medicine
Referral may be required

University Of Alabama Health Services Foundation PC

2000 6th Ave S, 
Birmingham, AL 
 (359.6 miles away)
205-996-5864
Languages Spoken:
English
See accepted insurances

Mark Dransfield is an Intensive Care Medicine provider practicing medicine in Birmingham, Alabama. Dr. Dransfield is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Bronchitis, Endoscopy, and Lung Transplant.

Frequently Asked Questions about Dr. Jan Westerman

How do I make an appointment with Dr. Jan Westerman?

You can book an appointment with Dr. Jan Westerman by calling their office at 205-387-7555. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jan Westerman a top-rated expert for Obstructive Sleep Apnea?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jan Westerman is classified as an Advanced expert for Obstructive Sleep Apnea, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jan Westerman specialize in?

While Dr. Jan Westerman is a Intensive Care Medicine, they have specific expertise in Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease (COPD), and Excessive Daytime Sleepiness. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Intensive Care Medicine.

Does Dr. Jan Westerman participate in research or clinical trials?

Yes. Dr. Jan Westerman has published 1 articles and abstracts on conditions like Obstructive Sleep Apnea. You can view a list of Dr. Jan Westerman's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jan Westerman accept my insurance?

Dr. Jan Westerman accepts most major insurance plans, including Aetna and Alliant Health. We recommend calling the office directly at 205-387-7555 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Westerman's expertise for a condition
ConditionClose
      View All 34 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile